

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number  
**WO 2005/061439 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 233/80**,  
C07D 213/75, A61K 31/165, 31/44, A61P 25/06

(21) International Application Number:  
PCT/US2004/038226

(22) International Filing Date: 6 December 2004 (06.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/530,463 17 December 2003 (17.12.2003) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOHLMAN, Daniel, Timothy** [US/US]; 6281 East Old Otto Court, Camby, Indiana 46113 (US). **VICTOR, Frantz** [US/US]; 4855 North Tuxedo Street, Indianapolis, Indiana 46205 (US). **XU, Yao-Chang** [US/US]; 10815 Timber Springs Drive East, Fishers, Indiana 46038 (US). **YING, Bai-Ping** [US/US]; 7717 Hidden Ridge, Fishers, Indiana 46038 (US). **ZHANG, Deyi** [US/US]; 1372 Kirklees Drive, Carmel, Indiana 46032 (US).

(74) Agents: **TUCKER, R., Craig** et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,

[Continued on next page]

(54) Title: SUBSTITUTED (4-AMINOCYCLOHEXEN-1-YL)PHENYL AND (4-AMINOCYCLOHEXEN-1-YL)PYRIDINYL COMPOUNDS AS 5-HT<sub>1F</sub> AGONISTS



(I)

(57) Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is -C(R<sup>4</sup>)= or -N=; Ar is phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R<sup>1</sup> and R<sup>2</sup> are independently hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl; R<sup>3</sup> is hydrogen, fluoro, or methyl; when X is -C(R<sup>4</sup>)=, R<sup>4</sup> is hydrogen, fluoro, or methyl, provided that no more than one of R<sup>3</sup> and R<sup>4</sup> may be other than hydrogen; and R<sup>5</sup> is hydrogen, methyl, or ethyl. The compounds of the present invention are useful for activating 5-HT<sub>1F</sub> receptors, inhibiting dural

protein extravasation, and for the treatment or prevention of migraine in a mammal.